Expanding chemical space to drug challenging disease targets
Our Advantage
Our unparalleled platform has potential to enable higher quality and diversity of drug candidates for challenging, difficult-to-drug disease targets.
By expanding and enriching accessible chemical space, our platform enables not just discovery of small molecule modulators but also enables targeted protein degradation, antibody-drug conjugates, and other therapeutic strategies.
The Zymergen
ApProach
- Our metagenomic database provides access to an untapped universe of novel chemical matter.
- Proprietary data science tools predict molecules with bioactivity against specific proteins of interest.
- Zymergen’s synthetic biology platform enables us to make complex molecules others cannot.
- Advanced chemoinformatics capabilities enable modeling of protein interactions with novel natural products and virtual screening.
- Synthetic biology analoging tools combined with synthetic chemistry have the potential to derisk and accelerate lead optimization.
OUR
PLATFORM
Our platform combines our three core competencies — metagenomics, machine learning, and synthetic biology.
METAGENOMICS
Our metagenomic database is one of the largest of its kind – providing us unique access to millions of novel bioactives.
MACHINE
LEARNING
Our proven ML tools search and enrich for the most promising chemical candidates, going from millions of potential leads to dozens in weeks, all in silico.
SYNTHETIC
BIOLOGY
Our proprietary synthetic biology platform can engineer microbes to make a wide range of complex compounds across a wide range of biological hosts.
Focus
Areas
ONCOLOGY
Unmet patient need in oncology is extremely high and innovation is critical to improve outcomes. We are focusing on well-validated synthetic lethal targets where our chemistry provides a competitive advantage.
PARTNERSHIPS
Our platform is applicable to a broad range of therapeutic targets. We are open to partnering with global leaders on targets of mutual interest. The first step in our process is to conduct an in silico target feasibility assessment.
Updates
March 6, 2022
Zymergen Announces Emerging Drug Discovery Business Enabled by One of the World’s Largest Metagenomics Databases and Proprietary Synthetic Biology Platform
January 9, 2022
LET’S
TALK
Ready to make the therapeutics of tomorrow?
Let’s talk today.